Modern antifungal therapy for neutropenic fever
Article
- 38 Downloads
Abstract
Empirical antifungal therapy has been shown to decrease the number of documented fungal infections in the setting of persistent fever during neutropenia. For decades, amphotericin B deoxycholate has been considered the agent of choice for first-line therapy in this setting. New antifungal agents associated with less toxicity, including the lipid formulations of amphotericin, voriconazole, and caspofungin, are now available and are considered to be suitable alternative first-line agents. In order to ensure appropriate therapy, however, the clinician must consider not only the differences between these antifungals but also patient-specific factors before initiating treatment.
Keywords
Voriconazole Caspofungin Neutropenic Patient Liposomal Amphotericin Ergot Alkaloid
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Pizzo PA, Robichaud KJ, Gill FA, et al.: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982, 72:101–111.PubMedCrossRefGoogle Scholar
- 2.EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989, 86:668–672.CrossRefGoogle Scholar
- 3.Hughes WT, Armstrong D, Bodey GP, et al.: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730–751. Guideline outlining risk factors and the appropriate use of antimicrobial agents in the setting of unexplained fever in neutropenic patients.PubMedCrossRefGoogle Scholar
- 4.Fleming RV, Kantarjian HM, Husni R, et al.: Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001, 40:511–520.PubMedCrossRefGoogle Scholar
- 5.Wingard JR, White MH, Anaissie E, et al.: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000, 31:1155–1163.PubMedCrossRefGoogle Scholar
- 6.Walsh TJ, Finberg RW, Arndt C, et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999, 340:764–771.PubMedCrossRefGoogle Scholar
- 7.Perea S and Patterson TF: Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002, 35:1073–1080.PubMedCrossRefGoogle Scholar
- 8.Amphocin® (amphotericin B) [prescribing information]. Kalamazoo, MI: Pharmacia; 2003.Google Scholar
- 9.VFEND® (voriconazole) [prescribing information]. New York, NY: Pfizer; 2005.Google Scholar
- 10.Boucher HW, Groll AH, Chiou CC, Walsh TJ: Newer systemic antifungal agents: pharmacokinetics, safety, and efficacy. Drugs 2004, 64:1997–2020.PubMedCrossRefGoogle Scholar
- 11.Johnson LB, Kauffman CA: Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003, 36:630–637.PubMedCrossRefGoogle Scholar
- 12.Cancidas® (caspofungin acetate) [prescribing information]. Whitehouse Station, NJ: Merck; 2005.Google Scholar
- 13.Frothingham R: Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. Clin Infect Dis 2002, 35:896–897.PubMedCrossRefGoogle Scholar
- 14.Prentice HG, Hann IM, Herbrecht R, et al.: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997, 98:711–718.PubMedCrossRefGoogle Scholar
- 15.Walsh TJ, Pappas P, Winston DJ, et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225–234. This randomized trial compared voriconazole to liposomal amphotericin B for empirical antifungal therapy in the setting of febrile neutropenia. Voriconazole did not meet the predefined noninferiority criteria set forth in this trial. However, when examining individual elements of the composite score, both treatment arms were found to be similar and voriconazole was superior in reducing documented breakthrough fungal infections. These findings, coupled with a better safety profile, make voriconazole an appealing alternative agent.PubMedCrossRefGoogle Scholar
- 16.Wingard JR: Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004, 39(Suppl 1):S38-S43.PubMedCrossRefGoogle Scholar
- 17.Walsh TJ, Teppler H, Donowitz GR, et al.: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351:1391–1402. This randomized trial compared caspofungin to liposomal amphotericin B for empirical antifungal therapy in the setting of febrile neutropenia. Caspofungin was found to be as effective as and better tolerated than liposomal amphotericin B, showing that caspofungin is a suitable alternative agent for empirical antifungal therapy.PubMedCrossRefGoogle Scholar
- 18.Ascioglu S, Rex JH, de Pauw B, et al.: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7–14. This international consensus guideline defines invasive fungal infections. These criteria were established to be used in clinical and epidemiologic research, allowing for comparisons between studies and avoiding differences in definitions between individual study groups.PubMedCrossRefGoogle Scholar
Copyright information
© Current Science Inc 2006